LoadingLoadingLoadingThe quick read
Latest quote·Oct 9
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNeither. Lantern Pharma Inc (LTRN) insiders filed no open-market purchases or sales in the 90 days to Oct 13, 2026, according to SEC Form 4 filings.
None. No member of Congress disclosed a LTRN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net buying.
Buys (2)
Schalop Lee Troy
$100K
bought
Keyser D Jeffrey
$100K
bought
No tracked top-trader positions in LTRN right now.
Live Hyperliquid positioning - not every stock is covered
Last report
May 15, 2026
Period ending
Mar 31, 2026
Earnings per share
-$0.36 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Mar 31, 2026 | May 15, 2026 | -$0.30 / -$0.36Alpha Vantage | +16.67% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 30, 2026 | -$0.36 / -$0.46Alpha Vantage | +21.74% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 12, 2025 | -$0.39 / -$0.47Alpha Vantage | +17.02% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 13, 2025 | -$0.40 / -$0.48Alpha Vantage | +16.67% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 15, 2025 | -$0.42 / -$0.43Alpha Vantage | +2.33% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 27, 2025 | -$0.54 / -$0.51Alpha Vantage | -5.88% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | -$0.42 / -$0.56Alpha Vantage | +25.00% beat | Unavailable | Unavailable |
| Jun 30, 2024 | Aug 8, 2024 | -$0.46 / -$0.55Alpha Vantage | +16.36% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | $4.5K | $4.1K | -$4.1K | $3.9K |
| Gross profit | -$4.5K | -$4.1K | $4.1K | -$3.9K |
| What it spent | ||||
| Research and development | $3.1M | $2.4M | $2.7M | $1.7M |
| Sales and admin | $1.5M | $1.9M | $1.5M | $1.7M |
| Other operating costs | $57.8K | — | — | — |
| Total operating expenses | $4.7M | $4.3M | $4.2M | $3.4M |
| What was left | ||||
| Operating profit | -$4.7M | -$4.3M | -$4.2M | -$3.4M |
| Profit before tax | -$4.3M | -$4.2M | -$4.1M | -$3.3M |
| Net profit | -$4.3M | -$4.2M | -$4.1M | -$3.3M |
| EBITDA | -$4.3M | -$4.2M | -$4.1M | -$3.3M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
